13 interactions on record
( 7.4 ) 7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone System Concomitant use of ENTRESTO with an ACE inhibitor is contraindicated because of the increased risk of angioedema [see Contraindications (4)] .
Source: FDA drug label - sacubitril and valsartan
7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use (7.1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia (7.3) 7.1 Potassium-Sparing Diuretics Use with potassium-sparing diuretic can produce severe hyperkalemia. 7.2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.
Source: FDA drug label - potassium chloride
7 DRUG INTERACTIONS The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3) Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) 7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia. 7.3 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.
Source: FDA drug label - potassium citrate
Drug interactions ACE inhibitors, Angiotensin II receptor antagonists, aldosterone blockers, potassium supplements, heparin, low molecular weight heparin, and other drugs known to cause hyperkalemia Concomitant administration may lead to severe hyperkalemia.
Source: FDA drug label - spironolactone and hydrochlorothiazide
DRSP causes an increase in plasma renin activity and plasma aldosterone induced by its mild anti-mineralocorticoid activity.
Source: FDA drug label - drospirenone and ethinyl estradiol
For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system. Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur.
Source: FDA drug label - captopril
For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system. Agents Increasing Serum Potassium : Since captopril decreases aldosterone production, elevation of serum potassium may occur.
Source: FDA drug label - captopril and hydrochlorothiazide
Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.
Source: FDA drug label - furosemide
Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.
Source: FDA drug label - furosemide, benzalkonium chloride
7 DRUG INTERACTIONS Agonistic effects (increase in Phenylephrine hydrochloride injection blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids ( 7.1 ) Antagonistic effects (decrease in Phenylephrine hydrochloride injection blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents ( 7.2 ) 7.1 Interactions that Augment Pressor Effect The increasing blood pressure effect of Phenylephrine hydrochloride injection is increased in patients receiving: Monoamine oxidase inhibitors (MAOI) Oxytocin and oxytocic drugs Tricyclic antidepressants Angiotensin, aldosterone Atropine Steroids, such as hydrocortisone Norepinephrine transporter inhibitors, such as atomoxetine Ergot alkaloids, such as methylergonovine maleate 7.2 Interactions that Antagonize the Pressor Effect The increasing blood pressure effect of Phenylephrine hydrochloride injection is decreased in patients receiving: • α-adrenergic antagonists • Phosphodiesterase Type 5 inhibitors • Mixed α- and β-receptor antagonists • Calcium channel blockers, such as nifedipine • Benzodiazepines • ACE inhibitors • Centrally acting sympatholytic agents, such as reserpine guanfacine.
Source: FDA drug label - phenylephrine hydrochloride
Other ACE inhibitors have had less than additive effects with beta adrenergic blockers, presumably because both drug classes lower blood pressure by inhibiting parts of the renin-angiotensin-aldosterone system. Therefore, concomitant use of telmisartan and ramipril is not recommended [see Dual Blockade of the Renin-Angiotensin-Aldosterone System ( 5.7 ) ].
Source: FDA drug label - ramipril
Examples of drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity.
Source: FDA drug label - spironolactone
7.4 Dual Blockade of the Renin-Angiotensin-Aldosterone System and Changes in Renal Function Dual blockade of the renin-angiotensin-aldosterone system (RAS) with angiotensin blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and renal impairment.
Source: FDA drug label - telmisartan and hydrochlorothiazide